Private equity investors GHO Capital Partners and Ampersand Capital Partners have announced a merger agreement for the ...

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

Avid Bioservices said on Wednesday that it would be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in a deal valued at about $1.1 billion. GHO and Ampersand have ...

The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

The definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid.

Under the terms of the merger agreement, GHO and Ampersand would acquire all the outstanding shares held by Avid’s stockholders for $12.50 per share in cash. The per share purchase price represents a ...

We are bullish on Avid's potential take-private deal by Ampersand and GHO, predicting value creation and optimistic about ...

Believes Proposed Offer of $12.50 / Share Significantly Undervalues the Company and Does Not Adequately Compensate Shareholders for Exceptional Growth Ahead Does Not Intend to Vote For the Deal and ...

GHO Capital Partners and Ampersand Capital Partners have agreed to acquire Avid Bioservices, a biologics contract development and manufacturing organization, in an all-cash transaction valued at ...

Integrating technology and sustainability is essential for optimising workplace efficiency and enhancing client experiences ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQ: CDMO) to ...